Developing new cancer treatments by targeting specific metabolic pathways
Rational design of anti-cancer therapeutics harnessing the synthetic lethality of methionine metabolism and arginine methyltransferases
This study is looking at a new drug called MTDIA that could help fight certain types of cancer, like colorectal cancer, by changing how cancer cells use nutrients, and it aims to find better treatment options for patients with specific genetic traits in their tumors.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10880400 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain cancer cells can be targeted by disrupting their metabolism, specifically through the manipulation of methionine and arginine pathways. The study investigates the effects of a novel drug, MTDIA, which inhibits tumor growth in various cancer models, including colorectal cancer. By combining this drug with other inhibitors, the research aims to enhance treatment efficacy for cancers that have specific genetic deletions. Patients may benefit from new therapeutic options that are tailored to their cancer's unique metabolic profile.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit MTAP deletions, particularly colorectal cancer.
Not a fit: Patients whose cancers do not have MTAP deletions or those with other unrelated cancer types may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with specific types of cancer, particularly those with MTAP deletions.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting metabolic pathways in cancer treatment, indicating potential for success in this area.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Bedard, Gabriel T — Albert Einstein College of Medicine
- Study coordinator: Bedard, Gabriel T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.